Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status

Giuseppe Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), E. Radaeli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Antonella Ravaggi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Elisabetta Cariani(University of Parma), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Angelo Rossini(Centro Universitário Barão de Mauá)
Blood
August 1, 1997
10.1182/blood.v90.3.1309
Cited by 46

Related Papers

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
|Blood|2008|253
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
|Journal of Clinical Oncology|2017|196